A single trial, declared as a first-in-human phase 1 trial testing CRISPR/Cas9 PD-1-edited T cells in patients with advanced NSCLC (NCT02793856), had results both published and posted in ClinicalTrials.gov. Here, PDCD1 is linked to non-small cell lung carcinoma.